Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYulia ShifrinJKJack KhouriCSChristy Samaras

Discussion

Loading...

Member takes

Overview

Novel method enumerates circulating tumor cells in myeloma, suggesting improved monitoring of minimal residual disease.

Key Points

  • To introduce a new method for evaluating minimal residual disease in multiple myeloma using liquid biopsies and 3D telomere profiling.
  • Isolated circulating tumor cells from peripheral blood of 14 myeloma patients at diagnosis and relapse.
  • Used immunophenotyping with CD56 and CD138 markers and 3D telomere profiling via TeloView software.
  • Analyzed nuclear volume and telomere characteristics of myeloma cells compared to normal lymphocytes.
  • Detected circulating tumor cells in all samples with high sensitivity.
  • CD56+/CD138+ myeloma cells exhibited higher nuclear volume and abnormal telomere profiles.
  • 3D telomere analysis differentiated myeloma cells from lymphocytes, indicating disease progression.

Cite This Study

Shifrin et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7dfhttps://doi.org/10.1182/blood-2025-2217
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isolation and profiling of single circulating tumor cells in myeloma: a new workflow for liquid biopsies2026
  2. 2Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  3. 3Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant2025
  4. 4From Spatial Heterogeneity to Real-Time Monitoring: Liquid Biopsy for Genomic Profiling and MRD Assessment in Multiple Myeloma2026
  5. 5Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights2026 · 1 citations